Evidence map›Paper›PMID 32116539›Full record

ReviewFrontiers in molecular neuroscience2019

Zebrafish as a Model System for the Study of Severe Ca

Sidharth Tyagi, Angeles B Ribera, Roger A Bannister

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Towards Zebrafish Models of CNS Channelopathies.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Complex effects on CaScientific reports · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Voltage-Gated CaFrontiers in synaptic neuroscience · 2021
    Review
  10. Review
  11. Sensing through Non-Sensing Ocular Ion Channels.International journal of molecular sciences · 2020
    Review
  12. Developing a pathway to clinical trials forTherapeutic advances in rare disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Sidharth TyagiMedical Scientist Training Program, Yale University School of Medicine, New Haven, CT, United States.
Angeles B RiberaDepartment of Physiology and Biophysics, University of Colorado School of Medicine, Aurora, CO, United States.
Roger A BannisterDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
University of Colorado Denver · USUniversity of Maryland, Baltimore · USYale University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Rad and amyotrophic lateral sclerosis (ALS)R01NS103777 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI HERNANDEZ-OCHOA, ERICK OMAR · 2018 to 2022
$1.7M
Neuronal Transdifferention in vivo: Mechanism and PotentialR01NS086839 · NINDS · UNIVERSITY OF COLORADO DENVER · PI RIBERA, ANGELES BADELL · 2014 to 2018
$1.7M
NIGMS NIH HHS T32 GM007205NINDS NIH HHS R01 NS086839NINDS NIH HHS R01 NS103777NINDS NIH HHS R56 NS103777
6 · The paper itself

Abstract

The P/Q-type Ca

Indexed as

CaV2.1channelopathyepisodic ataxia type 2familial hemiplegic migraine type 1P/Q-typevertebrate modelszebrafishα1A

Identifiers

PMID32116539
PMCPMC7018710
OpenAlexW3005404784

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.